Press Releases Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:18 13/02/2026 pm IST			5-day change	1st Jan Change
1,577.00 ^GBX	+0.38%		+2.40%	+1.74%

13/02	Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates	MT
11/02	OneSource Specialty Pharma Gets Approval to Commercialize Generic Version of Ozempic in Saudi Arabia	MT

Press Releases

11/02	Hikma Pharmaceuticals : R&D. Innovation in clinical research. Meet Hiba Kamal	PU
03/02	Client Update: Supreme Court Takes Up Skinny Labels Granting Certiorari In Hikma v. Amarin	AQ
19/01	Hikma announces launch of Enoby and Xtrenbo referencing Prolia and Xgeva respectively	AQ
19/01	Hikma Pharmaceuticals : announces launch of Enoby™ (denosumab- qbde) and Xtrenbo™ (denosumab- qbde) referencing Prolia® and Xgeva® respect...	PU
15/01	Hikma Pharmaceuticals : achieves B scores in Climate Change and Water Security in 2025 CDP assessment	PU
07/01	Hikma Pharmaceuticals : Exploring partnership opportunities with Hikma Pharmaceuticals	PU
17/12	Hikma Pharmaceuticals : full year 2025 aide memoire	PU
15/12	Hikma Pharmaceuticals : Inspiring women of Hikma - Meet Cristina Cagnazzi, Finance Director, Hikma Italy	PU
08/12	European Injectables growth: a Q&A with Nassim Rahmani, Associate VP, Commercial Europe & Canada	PU
08/12	Hikma Pharmaceuticals : launches TYZAVAN™ (vancomycin injection, USP) in the US	PU
27/11	Hikma Pharmaceuticals : Jefferies London Healthcare Conference Transcript	PU
24/11	Hikma Pharmaceuticals : Inspiring women of Hikma - Meet Susana Pereira Sr. Director Quality Systems & Validation – EU & MENA Injectables	PU
20/11	Hikma Pharmaceuticals : celebrates 20 years on the London Stock Exchange	PU
19/11	Strategic Priorities in Hikma Pharmaceuticals R&D: Q&A with Hafrun Fridriksdottir, EVP, Rx and R&D	PU
11/11	Hikma Launches Ustekinumab Biosimilar STARJEMZA	AQ
10/11	Hikma Pharmaceuticals : R&D. Innovating Formulation Development. Meet Razan Alsawwaf	PU
06/11	Hikma Pharmaceuticals : November 2025 Trading Update	PU
06/11	Hikma Pharmaceuticals : announces the launch of STARJEMZA™ (ustekinumab-hmny) Injection, a biosimilar referencing STELARA®...	PU
23/25/23	Hikma Pharmaceuticals : R&D. Innovating analytical development. Meet Edvin Brusač	PU
23/25/23	Hikma Pharmaceuticals : R&D. Innovating formulation development. Meet Edvin Brusač	PU
15/25/15	Hikma Pharmaceuticals : R&D. Innovating formulation development. Meet Anas Abdull-kareem Younues	PU
06/25/06	Hikma Pharmaceuticals : and Celltrion strengthen partnership to expand biosimilar access in MENA	PU
03/25/03	Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia	PU
29/25/29	Hikma Pharmaceuticals : R&D Innovating formulation development. Meet Helena Sremec	PU
29/25/29	Hikma Pharmaceuticals : and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbd...	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Hikma Pharmaceuticals faces tougher path to re-rating

January 09, 2026 at 02:41 pm IST